FDA commissioner says more ‘deregulatory’ action coming soonnews2025-10-31T17:33:28+00:00October 31st, 2025|Endpoints News|
Drugmakers are having frequent ‘most favored nation’ talks with White Housenews2025-10-31T15:57:39+00:00October 31st, 2025|Endpoints News|
Why are BridgeBio and Alnylam both seeing strong growth for their heart drugs?news2025-10-31T15:34:28+00:00October 31st, 2025|Endpoints News|
4DMT licenses eye gene therapy to Otsuka in Asia-Pacific; Arcus’ $250M offeringnews2025-10-31T14:45:46+00:00October 31st, 2025|Endpoints News|
What would Metsera bring to Novo Nordisk?news2025-10-31T11:32:14+00:00October 31st, 2025|Endpoints News|
OrbiMed-backed biotech quickly changes CEOs; Adaptimmune co-founder to lead Evaxionnews2025-10-31T11:00:30+00:00October 31st, 2025|Endpoints News|
Post-Hoc Live: Meet the scientists behind Baby KJ’s life-saving CRISPR therapynews2025-10-31T11:00:14+00:00October 31st, 2025|Endpoints News|
Vesper Bio reports early biomarker data for neurodegenerative disease candidatenews2025-10-31T10:57:21+00:00October 31st, 2025|Endpoints News|
Gilead sees cell therapy sales decline in Q3news2025-10-31T01:45:15+00:00October 31st, 2025|Endpoints News|
Novo’s Metsera offer could pose a test for Trump’s FTCnews2025-10-30T19:50:23+00:00October 30th, 2025|Endpoints News|
